Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China · Delayed Price · Currency is CNY | Market Cap | 20.60B +102.5% |
| Revenue (ttm) | 15.96B -1.5% |
| Net Income | 309.80M -53.4% |
| EPS | 0.12 -54.1% |
| Shares Out | 2.52B |
| PE Ratio | 68.36 |
| Forward PE | 45.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 245,001,857 |
| Open | 8.21 |
| Previous Close | 8.21 |
| Day's Range | 8.03 - 8.30 |
| 52-Week Range | 2.84 - 9.27 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About SHA:600664
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solut... [Read more]
Financial Performance
In 2025, SHA:600664's revenue was 15.96 billion, a decrease of -1.31% compared to the previous year's 16.18 billion. Earnings were 361.60 million, a decrease of -42.50%.
Financial StatementsNews
Why buyout funds, not IPOs, may define China’s next capital market cycle: Zhang Yichen
Zhang Yichen is chairman and CEO of Citic Capital Holdings, one of the leading players in China’s capital market, and the chairman of Trustar Capital. He heads several companies, including the McDonal...
Citic Capital CEO on making China a financial powerhouse
Zhang Yichen is chairman and CEO of Citic Capital Holdings, one of the leading players in China’s capital market, and the chairman of Trustar Capital. He heads several companies, including the McDonal...